Grace Therapeutics Inc. has shared a corporate presentation detailing their recent advancements and initiatives. The presentation highlights GTx-104, a novel intravenous formulation of nimodipine, developed to address the challenges associated with the current standard of care, which is available only in oral form. This new therapy has shown promising results in a pivotal Phase 3 STRIVE-ON safety trial, achieving its primary endpoint and demonstrating clinical benefits over the oral version. The presentation also mentions the submission of a New Drug Application (NDA) in June 2025, alongside the potential of GTx-104 to address severe rare diseases under Orphan Drug Status, granting it seven-year market exclusivity and multi-layered intellectual property protection. The context provided emphasizes the significant unmet needs in treating aneurysmal Subarachnoid Hemorrhage (aSAH), a condition with high mortality rates that affects relatively young patients. You can access the full presentation through the link below.